Skip to main content

Sars-Cov-2 Mrna (Tozinameran 6M-4Y) Vaccine Dosage

Applies to the following strengths: preservative-free

Usual Pediatric Dose for COVID-19

For investigational use only

6 months through 4 years: 0.2 mL IM for 3 doses, with the initial 2 doses administered 3 weeks apart, and then the third dose administered at least 8 weeks after the second dose


Use: Active immunization to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2)

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Patients turning 4 to 5 years during the primary series:



Safety and efficacy have not been established in patients younger than 6 months; an EUA is in effect for the use of an experimental vaccine to prevent COVID-19 in patients from 6 months to less than 5 years of age; this drug is not recommended for use in younger patients.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:

Storage requirements:

Reconstitution/preparation techniques:


Patient advice:

More about sars-cov-2 mrna (tozinameran 6m-4y) vaccine

Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.